Supriya Lifescience Limited, established as a partnership in 1985 and incorporated as a public limited company in 2008, specializes in the production and export of active pharmaceutical ingredients (APIs). With a strong emphasis on research and development, the company offers 39 niche APIs across therapeutic segments such as antihistamine, analgesic, and anti-asthmatic. It is a leading exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride, contributing significantly to API exports from India. Supriya Lifescience's products are internationally recognized, with approvals from major regulatory authorities including USFDA and EUGMP.
The company's operations are bolstered by a modern manufacturing facility in Maharashtra and recent expansions to enhance capacity and backward integration. Supriya Lifescience went public in December 2021, raising Rs 700 crore, and continues to invest in infrastructure, including a new R&D lab and additional manufacturing facilities. This strategic growth aims to expand its market presence and enhance production capabilities.
